Exondys 51 Recent News
Exclusive: Capricor CEO Talks Exondys Competition
Here's Why Sarepta Therapeutics May Be The Rarest Of Finds: A 'Value' Biotech Stock
Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys
The Street Is Misreading Sarepta's Guidance
Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
FDA 101: What Does 'Orphan Drug Designation' Mean?
For Sapreta, Today's Good News Might Be Just The Beginning
Sarepta Soars Following Encouraging Exondys 51 News
Credit Suisse Says Sarepta Shares Volatile, Still A Favorite Idea
2016's Most Hyped Events: How Did It Work Out For The Stocks?
The Rise And Fall Of Sarepta's Stock Since Exondys 51 Accelerated Approval
Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
For Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform
Sarepta Shares Continue Rally As Analysts Flip To Positive
Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform